NovaBay Pharmaceuticals, Inc. (NBY)

Compare

0.5623

-0.0097

(-1.70%)

At close: April 3 at 4:00:00 PM EDT

0.5500

-0.01

(-2.19%)

After hours: April 3 at 6:27:57 PM EDT

NovaBay Pharmaceuticals to Hold Special Meeting of Stockholders

EMERYVILLE, Calif., March 07, 2025--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") announces it will hold a virtual Special Meeting on April 16, 2025, at which stockholders will vote on a proposal for the liquidation and dissolution of the Company under Delaware law, pursuant to the Plan of Complete Liquidation and Dissolution of the Company (the "Dissolution"). The Special Meeting was announced in a preliminary proxy statement on Schedule 14A filed with the Sec

Business Wire 27 days ago

NBY
-1.70%
NovaBay Pharmaceuticals Completes the Sale of its Eyecare Business to PRN and Further Adjourns its Special Meeting of Stockholders on Dissolution Proposal

EMERYVILLE, Calif., January 23, 2025--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") announces the completion of the sale of its Avenova eyecare business and related assets to PRN Physician Recommended Nutriceuticals, LLC ("PRN") for $11.5 million (the "Asset Sale"). The Asset Sale, representing substantially all of the assets of the Company, was consummated pursuant to the Asset Purchase Agreement dated September 19, 2024, as amended, which NovaBay stockholders

Business Wire 2 months ago

NBY
-1.70%
NovaBay Pharmaceuticals (NBY) Upgraded to Buy: Here's Why

NovaBay Pharmaceuticals (NBY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks 3 months ago

NBY
-1.70%
NovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of Stockholders

EMERYVILLE, Calif., December 19, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") announces that its Reconvened Special Meeting of Stockholders held on December 18, 2024 has been adjourned until January 16, 2025 at 11:00 a.m. Pacific time to provide stockholders additional time to vote on Proposal One and Proposal Two. Both proposals received significant support based on the shares that have been voted by stockholders but have yet to reach the 50% threshold

Business Wire 3 months ago

NBY
-1.70%
NovaBay CEO Letter to Stockholders Urges a FOR Vote at Upcoming Reconvened Special Meeting

EMERYVILLE, Calif., December 09, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") announces that Chief Executive Officer Justin Hall has issued the following Letter to Stockholders:

Business Wire 3 months ago

NBY
-1.70%
NovaBay Pharmaceuticals to Reconvene Special Meeting of Stockholders on December 18, 2024

EMERYVILLE, Calif., November 22, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") announces that its Special Meeting of Stockholders held on November 22, 2024 has been adjourned until December 18, 2024 at 11:00 a.m. Pacific time to provide stockholders additional time to vote on Proposal One and Proposal Two. Both proposals received significant support based on the shares that have been voted by stockholders but have yet to reach the 50% threshold of favorab

Business Wire 4 months ago

NBY
-1.70%
Prominent Independent Proxy Advisory Firm ISS Supports NovaBay Pharmaceuticals’ Proposals to Authorize the Sale of its Avenova Brand

EMERYVILLE, Calif., November 15, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") announces that the largest institutional advisory firm, Institutional Shareholder Services (ISS), has recommended that NovaBay stockholders vote in favor of all of the Company’s proxy proposals, specifically to authorize and approve the sale of its eyecare business (the "Asset Sale Proposal") and approve the voluntary liquidation and dissolution of the Company (the "Dissolution

Business Wire 4 months ago

NBY
-1.70%
NovaBay Pharmaceuticals Reports Third Quarter 2024 Financial Results

EMERYVILLE, Calif., November 07, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and nine months ended September 30, 2024.

Business Wire 4 months ago

NBY
-1.70%
NovaBay Pharmaceuticals Accepts Revised Offer from PRN Physician Recommended Nutriceuticals, LLC and Enters into an Amendment to the Asset Purchase Agreement to Increase Purchase Price

EMERYVILLE, Calif., November 06, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") today announces that the Company has accepted a revised transaction proposal from PRN Physician Recommended Nutriceuticals, LLC ("PRN") to increase the base purchase price for the Company’s eyecare business from $9.5 million to $11.5 million. The Company has entered into an amendment (the "Amendment") to its previously announced Asset Purchase Agreement, dated September 19, 202

Business Wire 4 months ago

NBY
-1.70%
NovaBay Pharmaceuticals Board Determines Unsolicited Offer is Superior to Asset Purchase Agreement with PRN Physician Recommended Nutriceuticals, LLC

EMERYVILLE, Calif., October 29, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") announces that the Company’s board of directors has determined that an unsolicited and non-binding offer from Refresh Acquisitions BidCo LLC ("Refresh") for an affiliate of Refresh to acquire the Company’s Avenova® brand and related assets is a "Superior Proposal" to the Company’s asset purchase agreement with PRN Physician Recommended Nutriceuticals, LLC ("PRN").

Business Wire 5 months ago

NBY
-1.70%
Acumen Health Holdings ("Acumen") to Acquire the Avenova brand from NovaBay Pharmaceuticals

Acumen Health Holdings, LLC, a professionally recommended, consumer-preferred dietary supplements company focused on eye health and companion animals, announced today that its subsidiary, PRN Physician Recommended Nutriceuticals, LLC, has entered into a definitive asset purchase agreement to acquire the assets of the Avenova® brand (the "Brand") and business from NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay"). The Brand offers several products for ocular health including cleansi

PR Newswire 6 months ago

NBY
-1.70%
NovaBay Pharmaceuticals Signs Definitive Agreement to Sell its Avenova Assets

EMERYVILLE, Calif., September 20, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") announces it has entered into a definitive asset purchase agreement (the "Agreement") with PRN Physician Recommended Nutriceuticals, LLC ("PRN") to sell the assets of its Avenova® brand and business for $9.5 million in cash. The transaction has been approved by the Company’s board of directors and is anticipated to close in the fourth quarter of 2024, subject to the satisfacti

Business Wire 6 months ago

NBY
-1.70%
NovaBay Pharmaceuticals Reports Second Quarter 2024 Financial Results

EMERYVILLE, Calif., August 13, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and six months ended June 30, 2024 and provides a business update.

Business Wire 7 months ago

NBY
-1.70%
NovaBay Pharmaceuticals to Hold Second Quarter 2024 Conference Call on August 13, 2024

EMERYVILLE, Calif., August 01, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and six months ended June 30, 2024 after market close on Tuesday, August 13, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time.

Business Wire 7 months ago

NBY
-1.70%
NovaBay Pharmaceuticals Reports Record Amazon Prime Day Sales

EMERYVILLE, Calif., July 30, 2024--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) reports record sales of Avenova®-branded eyecare products during the Amazon Prime Day event, which was held July 16-17, 2024. Over the two-day period, Avenova sales were 17% higher compared with Prime Day 2023 and were up 40% over Prime Day 2022.

Business Wire 7 months ago

NBY
-1.70%
NovaBay Pharmaceuticals Announces Closing of $3.87 Million Underwritten Public Offering, Including Partial Exercise of Overallotment Option

EMERYVILLE, Calif., July 29, 2024--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) (the "Company" or "NovaBay") today announced the closing of its previously announced underwritten public offering of common stock, pre-funded warrants, Series F-1 warrants, Series F-2 warrants and Series F-3 warrants for gross proceeds of approximately $3.87 million, prior to deducting underwriting discounts and commissions and offering expenses. The offering proceeds include partial exercise of the underwriter

Business Wire 8 months ago

NBY
-1.70%
NovaBay Pharmaceuticals Announces Pricing of $3.5 Million Underwritten Public Offering

EMERYVILLE, Calif., July 26, 2024--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) (the "Company" or "NovaBay"), today announced the pricing of its underwritten public offering of 3,200,380 shares of common stock (or pre-funded warrants in lieu thereof), 3,200,380 Series F-1 warrants to purchase up to 3,200,380 shares of common stock, 3,200,380 Series F-2 warrants to purchase up to 3,200,380 shares of common stock and 3,200,380 Series F-3 warrants to purchase up to 3,200,380 shares of common

Business Wire 8 months ago

NBY
-1.70%
NovaBay Pharmaceuticals Offers 20% Discounts on Avenova Eyecare Products During Amazon Prime Day

EMERYVILLE, Calif., July 16, 2024--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces 20% discounts on Avenova®-branded eyecare products and product bundles during Amazon Prime Day being held July 16-17, 2024.

Business Wire 8 months ago

NBY
-1.70%
NovaBay Pharmaceuticals Reports Preliminary Second Quarter 2024 Net Revenue of $2.4 Million

EMERYVILLE, Calif., July 11, 2024--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) (the "Company" or "NovaBay") announces preliminary net revenue for the second quarter of 2024 of $2.4 million and for the first half of 2024 of $5.0 million, primarily derived from the Company’s eyecare products. Net revenue from the Company’s eyecare products increased by 9% for both the second quarter and the first half of 2024 over the corresponding periods in 2023. NovaBay also expects 2024 net revenue from

Business Wire 8 months ago

NBY
-1.70%
NovaBay Pharmaceuticals and Eyenovia Commence Co-Promotion Activities

EMERYVILLE, Calif. & NEW YORK, July 01, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare products, and Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, have commenced activities under a previously announced co-promotion agreement.

Business Wire 8 months ago

EYEN

NBY
-1.70%

Performance Overview

Return	NBY	S&P 500 (^GSPC)
YTD	-6.28%	-8.25%
1-Year	-83.93%	+3.55%
3-Year	-99.85%	+18.71%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

NovaBay Pharmaceuticals, Inc. (NBY)

NovaBay Pharmaceuticals to Hold Special Meeting of Stockholders

NovaBay Pharmaceuticals Completes the Sale of its Eyecare Business to PRN and Further Adjourns its Special Meeting of Stockholders on Dissolution Proposal

NovaBay Pharmaceuticals (NBY) Upgraded to Buy: Here's Why

NovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of Stockholders

NovaBay CEO Letter to Stockholders Urges a FOR Vote at Upcoming Reconvened Special Meeting

NovaBay Pharmaceuticals to Reconvene Special Meeting of Stockholders on December 18, 2024

Prominent Independent Proxy Advisory Firm ISS Supports NovaBay Pharmaceuticals’ Proposals to Authorize the Sale of its Avenova Brand

NovaBay Pharmaceuticals Reports Third Quarter 2024 Financial Results

NovaBay Pharmaceuticals Accepts Revised Offer from PRN Physician Recommended Nutriceuticals, LLC and Enters into an Amendment to the Asset Purchase Agreement to Increase Purchase Price

NovaBay Pharmaceuticals Board Determines Unsolicited Offer is Superior to Asset Purchase Agreement with PRN Physician Recommended Nutriceuticals, LLC

Acumen Health Holdings ("Acumen") to Acquire the Avenova brand from NovaBay Pharmaceuticals

NovaBay Pharmaceuticals Signs Definitive Agreement to Sell its Avenova Assets

NovaBay Pharmaceuticals Reports Second Quarter 2024 Financial Results

NovaBay Pharmaceuticals to Hold Second Quarter 2024 Conference Call on August 13, 2024

NovaBay Pharmaceuticals Reports Record Amazon Prime Day Sales

NovaBay Pharmaceuticals Announces Closing of $3.87 Million Underwritten Public Offering, Including Partial Exercise of Overallotment Option

NovaBay Pharmaceuticals Announces Pricing of $3.5 Million Underwritten Public Offering

NovaBay Pharmaceuticals Offers 20% Discounts on Avenova Eyecare Products During Amazon Prime Day

NovaBay Pharmaceuticals Reports Preliminary Second Quarter 2024 Net Revenue of $2.4 Million

NovaBay Pharmaceuticals and Eyenovia Commence Co-Promotion Activities

Performance Overview